Statins and Cognitive Impairment: Mechanisms, Evidence, and Research Directions

Background: Statins are among the most widely prescribed medications for cardiovascular prevention, yet concerns about their potential effects on cognition remain unresolved.Given their extensive and often lifelong use in aging populations, even modest cognitive effects could carry important clinical implications.Methods: We narratively reviewed biological and clinical data regarding the relationship between statin therapy and cognition, focusing on proposed mechanisms, regulatory safety signals, randomized trials, and large-scale observational studies.Particular attention was paid to the directionality of effects (neurotoxic versus neuroprotective), heterogeneity across statin types, lipophilicity, treatment intensities, and differences in cognitive endpoints, follow-up duration, and risk profiles of the underlying populations.Results: Biological evidence suggests dual and sometimes opposing mechanisms.Inhibition of the mevalonate pathway may lower coenzyme Q10, impair protein prenylation, and reduce neuronal cholesterol, potentially compromising mitochondrial bioenergetics, synaptic function, membrane integrity, and neuronal signaling.Conversely, statins' lipid-lowering, vascular, and anti-inflammatory actions can improve endothelial integrity, stabilize atherosclerotic plaques, and reduce cerebrovascular injury and microvascular damage, thereby supporting neuroprotection.Clinically, case reports and pharmacovigilance data describe reversible memory disturbances that have prompted regulatory warnings and heightened patient concern.However, findings from randomized trials and observational cohorts are inconsistent.Some studies report increased cognitive complaints or subtle decrements in memory performance among statin users, whereas others suggest a lower incidence of dementia, reduced stroke burden, and slower cognitive decline with long-term exposure.These discrepancies likely reflect variation in study design, baseline vascular and cognitive risk, statin type and dosage, adherence patterns, and the sensitivity of cognitive assessments, as well as residual confounding and limited follow-up in many datasets.Conclusions: Overall, current evidence does not support a consistent or clinically significant adverse effect of statins on global cognition or dementia risk, and the substantial cardiovascular benefits of statin therapy remain clear.Nonetheless, short-term cognitive symptoms and long-term dementia outcomes have rarely been evaluated within a unified framework.Future research should incorporate prospective designs with standardized neuropsychological batteries, rigorous exposure characterization, relevant fluid and imaging biomarkers, and extended follow-up into late life.Such studies will be essential to disentangle causal effects, identify susceptible subgroups, and optimize statin use for both cardiovascular and cognitive health.